Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH TM technology in a pre-clinical setting. The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical development team. Earlier in 2025, initial pre-clinical studies covered by the MTA, which examined pharmacokinetics in animals, had been completed. At that time, Lexaria had been informed by PharmaCO that they wished to review the pending safety (adverse events), pharmac
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Bioscience (NASDAQ:LEXX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic? [Yahoo! Finance]Yahoo! Finance
- Lexaria Bioscience (NASDAQ:LEXX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LEXX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Lexaria Bioscience (NASDAQ:LEXX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lexaria Bioscience (NASDAQ:LEXX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
LEXX
Sec Filings
- 12/5/25 - Form POS
- 12/5/25 - Form S-1/A
- 11/28/25 - Form 10-K
- LEXX's page on the SEC website